Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer at ASCO GU 2016
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content